This is also called metastatic breast cancer, advanced breast cancer, or stage 4 breast cancer Atezolizumab is a type of immunotherapy drug called a checkpoint inhibitor. It works by blocking a ...

Patients with HCC treated with a combination of the immune checkpoint inhibitor atezolizumab and angiogenesis inhibitor bevacizumab after resection or ablation showed a 28% improvement in ...

The Food and Drug Administration (FDA) has approved Tecentriq Hybreza ™ (atezolizumab and hyaluronidase-tqjs) for subcutaneous (SC) injection, for all the approved adult indications of ...

The US Food and Drug Administration (FDA) has approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) as a subcutaneous injection in adults, covering all approved ...

Oxaliplatin Added to Fluoropyrimidine/Bevacizumab as Initial Therapy for Unresectable Metastatic Colorectal Cancer in Older Patients: A Multicenter, Randomized, Open ...

Tecentriq Hybreza is supplied in a single-dose vial containing 1875 mg of atezolizumab and 30,000 units of hyaluronidase per 15 mL. The US Food and Drug Administration (FDA) has approved Tecentriq ...

The agency approved the subcutaneous injection of atezolizumab and hyaluronidase-tqjs for all of the adult indications as the intravenous formulation of atezolizumab. The FDA has approved the ...

According to the authors, data from the CONTACT-02 trial show that cabozantinib plus atezolizumab may benefit selected patients with mCRPC. Data from the final overall survival (OS) analysis from the ...

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Thymic Carcinoma. According to GlobalData, Phase II drugs for Thymic Carcinoma does not have sufficient ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. Targeted therapies and ...